Oncolytics Biotech (Oncolytics Biotech) Piotroski F-Score : 0 (As of Apr. 28, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Oncolytics Biotech has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Oncolytics Biotech's Piotroski F-Score or its related term are showing as below:

During the past 13 years, the highest Piotroski F-Score of Oncolytics Biotech was 4. The lowest was 0. And the median was 3.

Oncolytics Biotech Piotroski F-Score Historical Data

The historical data trend for Oncolytics Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Piotroski F-Score Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Piotroski F-Score

Get a 7-Day Free Trial

1.00

4.00

3.00

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Piotroski F-Score	Get a 7-Day Free Trial															3.00	-	1.00	1.00	-

How is the Piotroski F-Score calculated?

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Net Income was -4.704 + -5.601 + -7.335 + -2.944 = $-20.58 Mil.
Cash Flow from Operations was -5.722 + -6.371 + -4.456 + -4.565 = $-21.11 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(27.482 + 25.819 + 24.06 + 34.062 + 28.936) / 5 = $28.0718 Mil.
Total Assets at the begining of this year (Dec22) was $27.48 Mil.
Long-Term Debt & Capital Lease Obligation was $0.22 Mil.
Total Current Assets was $28.45 Mil.
Total Current Liabilities was $3.16 Mil.

Net Income was -5.355 + -3.979 + -3.305 + -6.297 = $-18.94 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(35.844 + 35.107 + 31.427 + 29.207 + 27.482) / 5 = $31.8134 Mil.
Total Assets at the begining of last year (Dec21) was $35.84 Mil.
Long-Term Debt & Capital Lease Obligation was $0.12 Mil.
Total Current Assets was $26.27 Mil.
Total Current Liabilities was $2.90 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Oncolytics Biotech's current Net Income (TTM) was -20.58. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Oncolytics Biotech's current Cash Flow from Operations (TTM) was -21.11. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)	=	Net Income	/	Total Assets (Dec22)
	=	-20.584	/	27.482
	=	-0.74899935

ROA (Last Year)	=	Net Income	/	Total Assets (Dec21)
	=	-18.936	/	35.844
	=	-0.52828925

Oncolytics Biotech's return on assets of this year was -0.74899935. Oncolytics Biotech's return on assets of last year was -0.52828925. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Oncolytics Biotech's current Net Income (TTM) was -20.58. Oncolytics Biotech's current Cash Flow from Operations (TTM) was -21.11. ==> -21.11 <= -20.58 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Dec22 to Dec23
	=	0.216	/	28.0718
	=	0.00769455

Gearing (Last Year: Dec22)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Dec21 to Dec22
	=	0.116	/	31.8134
	=	0.00364626

Oncolytics Biotech's gearing of this year was 0.00769455. Oncolytics Biotech's gearing of last year was 0.00364626. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)	=	Total Current Assets	/	Total Current Liabilities
	=	28.453	/	3.158
	=	9.00981634

Current Ratio (Last Year: Dec22)	=	Total Current Assets	/	Total Current Liabilities
	=	26.267	/	2.904
	=	9.04511019

Oncolytics Biotech's current ratio of this year was 9.00981634. Oncolytics Biotech's current ratio of last year was 9.04511019. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Oncolytics Biotech's number of shares in issue this year was 73.798. Oncolytics Biotech's number of shares in issue last year was 59.529. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

Gross Margin (Last Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

Oncolytics Biotech's gross margin of this year was . Oncolytics Biotech's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)	=	Revenue	/	Total Assets at the Beginning of This Year (Dec22)
	=	0	/	27.482
	=	0

Asset Turnover (Last Year)	=	Revenue	/	Total Assets at the Beginning of Last Year (Dec21)
	=	0	/	35.844
	=	0

Oncolytics Biotech's asset turnover of this year was 0. Oncolytics Biotech's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score

Que. 1

Que. 2

Que. 3

Que. 4

Que. 5

Que. 6

Que. 7

Que. 8

Que. 9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Oncolytics Biotech has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

Oncolytics Biotech (NAS:ONCY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

Oncolytics Biotech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Piotroski F-Score

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.